Corexa Pharmacy’s preliminary September revenue increased more than 66% from July, supported by retail customer growth and the launch of Tollo Health products.
Key Investor Takeaways
- DataMeds AI (NASDAQ:MEDS) said Corexa Pharmacy generated preliminary, unaudited September 2026 revenue of more than $1 million.
- Monthly revenue increased by more than 66% compared with July 2026, providing a measurable indication of recent growth at the pharmacy business.
- DataMeds attributed the increase to an expanding retail customer base, higher prescription volumes and sales of recently launched Tollo Health dietary supplements and medical foods.
- Corexa Pharmacy has also been added as a prescription fulfilment option within the Health Lives Here mobile application, potentially providing another customer acquisition channel.
- Management expects the pharmacy to become a model for Corexa Health’s network of more than 6,500 independent pharmacies, although no financial targets for that broader rollout were provided.
Why MEDS Stock Is in Focus
DataMeds AI reported that Corexa Pharmacy surpassed $1 million in preliminary, unaudited monthly revenue during September, up more than 66% from the level reported for July.
The increase follows the pharmacy’s rebranding during the first month of the third quarter of 2026. According to the company, growth came from both its retail customer base and the introduction of pharmaceutical-adjacent products from Tollo Health.
Management said Corexa is seeing increases in prescriptions filled alongside sales of dietary supplements and medical foods. The company is particularly positioning the pharmacy around patients using FDA-approved GLP-1 receptor agonist prescriptions and the Long COVID community.
Corexa Pharmacy is also available as a fulfilment option for telehealth prescriptions through the recently launched Health Lives Here mobile application.
Why This Matters for Investors
Crossing $1 million in monthly revenue gives investors a concrete operating metric for evaluating DataMeds’ pharmacy strategy. The more than 66% increase since July also suggests that recent commercial initiatives are beginning to translate into higher sales, although the September figure remains preliminary and unaudited.
The broader question is whether DataMeds can sustain that growth while connecting its pharmacy operations with its other healthcare assets. Management is attempting to combine prescription fulfilment, pharmaceutical-adjacent products, telehealth and its Health IT platforms within a vertically integrated model.
The recently completed Helomics acquisition could introduce another potential source of demand through oncology-related medications and nutritional support products. However, DataMeds did not quantify that potential demand or provide revenue guidance associated with the acquisition.
Corexa’s role within the company’s network strategy could also become significant. DataMeds plans to upgrade the pharmacy’s physical location as a flagship for its Health Lives Here initiative with NFL Alumni Health and use it as a model for pharmacies within Corexa Health’s network of more than 6,500 independent locations.
That creates a potential path for broader adoption, but the release does not establish how many network pharmacies will adopt the model or provide a timetable for expansion.
What to Watch Next
The next key indicator will be whether Corexa Pharmacy can maintain or build on its September revenue level and translate recent customer growth into sustained prescription and adjunct-product sales.
Investors can also watch for measurable adoption through the Health Lives Here app, integration of opportunities associated with Helomics, completion of the flagship pharmacy upgrade and evidence that the Health Lives Here model is being adopted across Corexa Health’s independent pharmacy network.